Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients.

Date publication

septembre 2019

Journal

Journal of the European Academy of Dermatology and Venereology : JEADV

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AUBIN François

Tous les auteurs :
Calugareanu A, Jachiet M, Tauber M, Nosbaum A, Aubin F, Misery L, Droitcourt C, Barbarot S, Debarbieux S, Saussine A, Bagot M, de Masson A, Sénéschal J, Staumont-Sallé,Bouaziz JD,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31529718

Résumé

Prurigo nodularis (PN) is a debilitating pruritic skin condition with an unmet therapeutic need (1). The mechanisms triggering PN are still unknown. Studies suggest the implication of the Th2 cytokine pathway (interleukin 4 (IL-4) and interleukin 13 (IL-13)) in its pathogenesis (2), evidenced by recent monocentric case series showing the efficacy of IL-4 and IL-13 blocker (dupilumab) for PN treatment (3-8).

Mots clés

atopic dermatitis, conjunctivitis, dupilumab, eosinophilia, prurigo nodularis

Référence

J Eur Acad Dermatol Venereol. 2019 Sep 17;: